Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 10—October 2010


Artesunate Misuse and Plasmodium falciparum Malaria in Traveler Returning from Africa

Dea Shahinas, Rachel Lau, Krishna Khairnar, David Hancock, and Dylan R. PillaiComments to Author 
Author affiliations: Author affiliations: University of Toronto, Toronto, Ontario, Canada (D. Shahinas, K. Khairnar, D.R. Pillai); Ontario Agency for Health Protection and Promotion, Toronto (R. Lau, D.R. Pillai); Ajax-Pickering Hospital, Ajax, Ontario, Canada (D. Hancock)

Main Article


Results of sequencing single-nucleotide polymorphisms of Plasmodium falciparum isolate*


pfmdr1 copy no.
CQ IC50, nmol/L
MQ IC50, nmol/L
ART IC50, nmol/L
3D7 N Y S N D A S 1.00 6.1 2.1 6.1
W2 Y Y S N D A S 0.97 252 3.2 7.3
Cameroon Y F S N D E N 1.85 163 7.7 8.07
Congo Y F S N D E N 1.51 355 10.7 10.9
Kenya Y F S N D E N 1.75 282 11.7 10.1
Liberia N F S N D E N 1.65 109 16.2 16.5
Nigeria C Y F S N D E N 1.06 222 8.7 8.1
Nigeria A N F S N D E N 1.52 171 16.6 20.1
Nigeria B Y F S N D E N 1.09 188 5.6 10.0
Ghana N F S N D E N 0.96 24.0 11.6 14.2
Tanzania Y F S N Y E N 1.88 381 7.8 16.6
Angola Y F S N D E N 0.81 258 4.5 7.3

* At Pfmdr1 and PfATPase6 residues previously implicated in artemisinin resistance and gene copy number of pfmdr1 by quantitative real-time PCR in relation to mean IC50 (n = 3) data for key drugs (7,8,10). pfmdr1, P. falciparum multidrug resistance 1; CQ, chloroquine; MQ, mefloquine; ART, artemisinin; IC50., 50% minimum inhibitory concentration; N, asparagine; Y, tyrosine; S, serine; D, aspartic acid; A, alanine; E, glutamic acid; 3D7, chloroquine-sensitive laboratory strain; W2, chloroquine-resistant laboratory strain; Nigeria A, clinical isolate described in this report.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO